- Home
- AU vs EW Comparison
AU vs EW Comparison
Compare AU & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AU | EW |
|---|---|---|
| Founded | 1944 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Industrial Specialties |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2B | 50.2B |
| IPO Year | 2023 | 1999 |
Fundamental Metrics
Financial Performance| Metric | AU | EW |
|---|---|---|
| Price | $92.76 | $82.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 21 |
| Target Price | ★ $119.00 | $96.37 |
| AVG Volume (30 Days) | 2.0M | ★ 4.8M |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.66 |
| Revenue | N/A | ★ $6,067,600,000.00 |
| Revenue This Year | $38.71 | $13.39 |
| Revenue Next Year | $2.89 | $9.81 |
| P/E Ratio | ★ $23.93 | $124.66 |
| Revenue Growth | N/A | ★ 11.55 |
| 52 Week Low | $42.17 | $72.30 |
| 52 Week High | $129.14 | $87.89 |
Technical Indicators
Market Signals| Indicator | AU | EW |
|---|---|---|
| Relative Strength Index (RSI) | 43.49 | 54.35 |
| Support Level | $90.76 | $81.39 |
| Resistance Level | $113.70 | $86.95 |
| Average True Range (ATR) | 3.43 | 2.44 |
| MACD | -0.82 | 0.11 |
| Stochastic Oscillator | 20.68 | 73.26 |
Price Performance
Historical ComparisonAbout AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.